Skip to main content
Caplight Logo









MEDIPOST Co., Ltd.

MEDIPOST Co., Ltd.

Public

MEDIPOST Co., Ltd. is now publicly traded

The data on this page reflects MEDIPOST Co., Ltd.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Early Funding

Jan 9, 2026

Total Funding Raised

$140M

Company Overview

MEDIPOST Co., Ltd. has raised $140M. It was founded in 2000.

MEDIPOST Co., Ltd. is a biotechnology company that develops and commercializes allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven and degenerative diseases.

AI Layer

Non-AI

MEDIPOST Co., Ltd. Comparables

Compare MEDIPOST Co., Ltd. with similar companies based on industry and business-model similarity.

No comparables are published for MEDIPOST Co., Ltd.. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

MEDIPOST Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJan 9, 2026
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Antonio S J Lee

CEO Managing Director

Executive Team

For institutional investors. Book with your work email.

MEDIPOST Co., Ltd. Investors

Notable investors and investment history

MEDIPOST Co., Ltd. investors
InvestorRounds
Crescendo Equity PartnersEarly Funding

MEDIPOST Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

MEDIPOST Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Firmographic Details

Headquarters—
Employee Range23
Year Founded2000
Last FundingJan 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?